Original articleDifferential T-cell and antibody responses induced by mRNA versus adenoviral vectored COVID-19 vaccines in patients with immunodeficiencies
Under a Creative Commons license
open access
Key words
COVID-19
SARS-CoV-2
vaccine
ChAdOx1-nCoV-19
BNT162b2
immunodeficiency
antibodies
T cells
immunoglobulins
health care workers
Abbreviations used
CEFT
Peptides pool from human cytomegalovirus, Epstein-Barr virus, influenza A virus, and Clostridium tetani
COVID-19
Coronavirus disease 2019
CVID
Common variable immunodeficiency
HCW
Health care worker
HCW-nPI
HCW with no prior COVID-19 infection
HCW-PI
HCW with prior COVID-19 infection
IDP
Immunodeficient patient
IgGRx
Immunoglobulin replacement therapy
PV1
Post first vaccine dose
PV2
Post second vaccine dose
RBD
Receptor binding domain
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Cited by (0)
The first 2 authors contributed equally to this article, and both should be considered first author. The last 2 authors contributed equally to this article, and both should be considered senior author.
Supported by the NIHR/UKRI (grant COV0170) Humoral Immune Correlates of COVID-19 (HICC), the NIHR/UK-HSA (MR/W02067X/1) SIREN study, the Royal Papworth Hospital NHS Foundation Trust Charity, and the Cambridge Commonwealth, European & International Trust (Cambridge Trust) in association with Cambridge–Africa.
Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.
© 2023 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.